Martin Julian Abrahamson, M.B.,Ch.B.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypoglycemic Agents | 24 | 2020 | 2877 | 1.750 |
Why?
|
| Diabetes Mellitus, Type 2 | 34 | 2020 | 11729 | 1.290 |
Why?
|
| Prediabetic State | 8 | 2018 | 499 | 0.860 |
Why?
|
| Insulin | 13 | 2016 | 6584 | 0.830 |
Why?
|
| Blood Glucose | 14 | 2020 | 6259 | 0.660 |
Why?
|
| Cooking | 1 | 2017 | 313 | 0.500 |
Why?
|
| Sulfonylurea Compounds | 1 | 2015 | 205 | 0.450 |
Why?
|
| Insulin, Long-Acting | 4 | 2020 | 57 | 0.450 |
Why?
|
| Diabetes Mellitus | 7 | 2015 | 5752 | 0.450 |
Why?
|
| Thiazolidinediones | 2 | 2004 | 475 | 0.370 |
Why?
|
| Health Education | 1 | 2017 | 1056 | 0.360 |
Why?
|
| Metformin | 2 | 2015 | 837 | 0.340 |
Why?
|
| Postprandial Period | 3 | 2019 | 293 | 0.290 |
Why?
|
| Algorithms | 9 | 2020 | 13869 | 0.270 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 1438 | 0.250 |
Why?
|
| Hyperglycemic Hyperosmolar Nonketotic Coma | 1 | 2004 | 24 | 0.240 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2006 | 336 | 0.230 |
Why?
|
| Blood Glucose Self-Monitoring | 4 | 2020 | 435 | 0.190 |
Why?
|
| Satiation | 1 | 2019 | 80 | 0.170 |
Why?
|
| Food, Formulated | 1 | 2019 | 109 | 0.170 |
Why?
|
| Life Style | 7 | 2018 | 3833 | 0.170 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2004 | 1203 | 0.160 |
Why?
|
| Hunger | 1 | 2019 | 198 | 0.160 |
Why?
|
| Diabetic Angiopathies | 3 | 2012 | 819 | 0.150 |
Why?
|
| Self Care | 2 | 2014 | 786 | 0.150 |
Why?
|
| Anticholesteremic Agents | 1 | 2004 | 979 | 0.150 |
Why?
|
| Diabetes Complications | 2 | 2015 | 1360 | 0.140 |
Why?
|
| Diet Therapy | 1 | 2018 | 154 | 0.140 |
Why?
|
| Hypoglycemia | 3 | 2018 | 861 | 0.140 |
Why?
|
| Weight Gain | 3 | 2018 | 2294 | 0.140 |
Why?
|
| Endocrinology | 3 | 2018 | 442 | 0.130 |
Why?
|
| Women's Health | 1 | 2004 | 2033 | 0.130 |
Why?
|
| Coronary Artery Disease | 1 | 2014 | 6485 | 0.120 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2014 | 87 | 0.120 |
Why?
|
| Comprehensive Health Care | 1 | 2015 | 127 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 1 | 4 | 2016 | 3338 | 0.120 |
Why?
|
| Self Efficacy | 1 | 2017 | 615 | 0.110 |
Why?
|
| Humans | 44 | 2020 | 743811 | 0.110 |
Why?
|
| Health Educators | 1 | 2011 | 20 | 0.100 |
Why?
|
| Hyperglycemia | 2 | 2015 | 1373 | 0.100 |
Why?
|
| Consensus | 5 | 2020 | 2954 | 0.100 |
Why?
|
| Decision Making | 2 | 2015 | 3887 | 0.100 |
Why?
|
| Health Status | 1 | 2004 | 4031 | 0.100 |
Why?
|
| Attitude of Health Personnel | 4 | 2014 | 3839 | 0.100 |
Why?
|
| Physician-Patient Relations | 3 | 2014 | 3229 | 0.100 |
Why?
|
| Communication Barriers | 1 | 2014 | 398 | 0.090 |
Why?
|
| Drug Combinations | 2 | 2020 | 1958 | 0.090 |
Why?
|
| Apolipoproteins B | 1 | 2012 | 374 | 0.090 |
Why?
|
| Hyperthyroxinemia | 1 | 1989 | 3 | 0.090 |
Why?
|
| Drug Administration Schedule | 2 | 2010 | 4931 | 0.080 |
Why?
|
| Administration, Oral | 2 | 2010 | 3912 | 0.080 |
Why?
|
| Hypertriglyceridemia | 1 | 2012 | 295 | 0.080 |
Why?
|
| Nutritional Status | 1 | 2017 | 1608 | 0.080 |
Why?
|
| Life Expectancy | 1 | 2015 | 1184 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2018 | 10940 | 0.080 |
Why?
|
| Medicare | 1 | 2006 | 6565 | 0.080 |
Why?
|
| Patient Preference | 1 | 2015 | 889 | 0.080 |
Why?
|
| United States | 13 | 2020 | 69859 | 0.070 |
Why?
|
| Triiodothyronine | 1 | 1989 | 494 | 0.070 |
Why?
|
| Age Factors | 3 | 2018 | 18355 | 0.070 |
Why?
|
| Formularies as Topic | 1 | 2006 | 91 | 0.070 |
Why?
|
| Thyroxine | 1 | 1989 | 667 | 0.060 |
Why?
|
| Primary Health Care | 3 | 2012 | 4556 | 0.060 |
Why?
|
| Comorbidity | 2 | 2018 | 10380 | 0.060 |
Why?
|
| Female | 21 | 2019 | 380020 | 0.060 |
Why?
|
| Disease Progression | 3 | 2007 | 13273 | 0.060 |
Why?
|
| History, 21st Century | 1 | 2010 | 1532 | 0.060 |
Why?
|
| Patient Education as Topic | 3 | 2018 | 2278 | 0.060 |
Why?
|
| Aged | 12 | 2019 | 163178 | 0.060 |
Why?
|
| Medication Adherence | 1 | 2015 | 2063 | 0.060 |
Why?
|
| Glyburide | 1 | 2004 | 113 | 0.060 |
Why?
|
| Qualitative Research | 4 | 2014 | 2682 | 0.060 |
Why?
|
| Internet | 1 | 2015 | 3058 | 0.060 |
Why?
|
| Patients | 1 | 2010 | 899 | 0.060 |
Why?
|
| Obesity | 7 | 2018 | 12744 | 0.050 |
Why?
|
| Weight Loss | 1 | 2014 | 2625 | 0.050 |
Why?
|
| Cholesterol, LDL | 1 | 2012 | 2354 | 0.050 |
Why?
|
| Carbamates | 1 | 2004 | 196 | 0.050 |
Why?
|
| Male | 19 | 2019 | 349776 | 0.050 |
Why?
|
| Insurance, Health | 1 | 2015 | 2492 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 3921 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2010 | 2736 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2012 | 2683 | 0.050 |
Why?
|
| Middle Aged | 15 | 2019 | 213241 | 0.050 |
Why?
|
| Exercise | 1 | 2018 | 5611 | 0.050 |
Why?
|
| Coronary Stenosis | 1 | 2007 | 833 | 0.050 |
Why?
|
| Attitude to Health | 1 | 2010 | 2052 | 0.050 |
Why?
|
| Autoantibodies | 1 | 1989 | 2037 | 0.050 |
Why?
|
| Emotions | 1 | 2012 | 2656 | 0.050 |
Why?
|
| Body Mass Index | 2 | 2015 | 12718 | 0.050 |
Why?
|
| Patient Care Team | 1 | 2011 | 2528 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 3255 | 0.050 |
Why?
|
| Insulin Resistance | 2 | 2004 | 3863 | 0.040 |
Why?
|
| Sirolimus | 1 | 2007 | 1565 | 0.040 |
Why?
|
| Islet Amyloid Polypeptide | 1 | 2019 | 41 | 0.040 |
Why?
|
| Cholecystokinin | 1 | 2019 | 115 | 0.040 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2003 | 430 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2004 | 2274 | 0.040 |
Why?
|
| Peptide YY | 1 | 2019 | 130 | 0.040 |
Why?
|
| Atherosclerosis | 1 | 2015 | 3445 | 0.040 |
Why?
|
| Voluntary Health Agencies | 1 | 2018 | 39 | 0.040 |
Why?
|
| Telemedicine | 1 | 2015 | 2874 | 0.040 |
Why?
|
| Risk Factors | 4 | 2015 | 72252 | 0.040 |
Why?
|
| Ghrelin | 1 | 2019 | 266 | 0.040 |
Why?
|
| Islets of Langerhans | 1 | 2004 | 1350 | 0.040 |
Why?
|
| Glucagon | 1 | 2019 | 533 | 0.040 |
Why?
|
| Adult | 11 | 2017 | 213889 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2004 | 1167 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2004 | 1372 | 0.040 |
Why?
|
| Exercise Therapy | 1 | 2003 | 904 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2013 | 4467 | 0.030 |
Why?
|
| Triazines | 1 | 2018 | 315 | 0.030 |
Why?
|
| Piperidines | 1 | 2004 | 1601 | 0.030 |
Why?
|
| Stents | 1 | 2007 | 3280 | 0.030 |
Why?
|
| Societies, Medical | 2 | 2018 | 3740 | 0.030 |
Why?
|
| Insulin Infusion Systems | 1 | 2016 | 212 | 0.030 |
Why?
|
| Insurance Coverage | 1 | 2006 | 1900 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2015 | 426 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2007 | 4152 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2004 | 2047 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 7908 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 2029 | 0.030 |
Why?
|
| Denmark | 1 | 2016 | 738 | 0.030 |
Why?
|
| Aspirin | 1 | 2006 | 3283 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2004 | 6487 | 0.030 |
Why?
|
| Acute Disease | 1 | 2004 | 7150 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2016 | 552 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 2016 | 1151 | 0.030 |
Why?
|
| Cardiovascular Diseases | 5 | 2016 | 15142 | 0.030 |
Why?
|
| Hypolipidemic Agents | 1 | 2018 | 606 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2014 | 11708 | 0.030 |
Why?
|
| Hyperlipidemias | 1 | 2018 | 789 | 0.030 |
Why?
|
| Physicians | 1 | 2011 | 4569 | 0.030 |
Why?
|
| Risk Assessment | 3 | 2014 | 23327 | 0.030 |
Why?
|
| Europe | 1 | 2018 | 3336 | 0.030 |
Why?
|
| Critical Illness | 1 | 2004 | 2670 | 0.020 |
Why?
|
| Leptin | 1 | 2019 | 1600 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2004 | 10251 | 0.020 |
Why?
|
| Decision Trees | 1 | 2013 | 506 | 0.020 |
Why?
|
| Appointments and Schedules | 1 | 2014 | 417 | 0.020 |
Why?
|
| Blood Pressure | 2 | 2016 | 8551 | 0.020 |
Why?
|
| Behavior Therapy | 1 | 2016 | 862 | 0.020 |
Why?
|
| Counseling | 1 | 2018 | 1523 | 0.020 |
Why?
|
| Treatment Outcome | 4 | 2014 | 63042 | 0.020 |
Why?
|
| Trust | 1 | 2014 | 505 | 0.020 |
Why?
|
| Quality of Life | 2 | 2014 | 12788 | 0.020 |
Why?
|
| Thyrotoxicosis | 1 | 1989 | 82 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2015 | 1885 | 0.020 |
Why?
|
| Disease Management | 1 | 2018 | 2459 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2003 | 9944 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2012 | 2298 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 3608 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 2018 | 2071 | 0.020 |
Why?
|
| Fear | 1 | 2014 | 1438 | 0.020 |
Why?
|
| Nutrition Surveys | 1 | 2012 | 1660 | 0.020 |
Why?
|
| Israel | 1 | 2007 | 796 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2014 | 5078 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2011 | 2453 | 0.010 |
Why?
|
| Prognosis | 1 | 2004 | 29052 | 0.010 |
Why?
|
| Lipids | 1 | 2014 | 3307 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2006 | 57744 | 0.010 |
Why?
|
| Platelet Aggregation | 1 | 2006 | 798 | 0.010 |
Why?
|
| Sleep | 1 | 2018 | 4619 | 0.010 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 3020 | 0.010 |
Why?
|
| Overweight | 1 | 2013 | 2371 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 7270 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 8637 | 0.010 |
Why?
|
| Communication | 1 | 2014 | 3748 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2006 | 1606 | 0.010 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2007 | 1874 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 2006 | 1813 | 0.010 |
Why?
|
| Boston | 1 | 2011 | 9310 | 0.010 |
Why?
|
| Hypertension | 1 | 2018 | 8480 | 0.010 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2007 | 1391 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2007 | 2217 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1989 | 12954 | 0.010 |
Why?
|
| Sex Factors | 1 | 2006 | 10394 | 0.010 |
Why?
|
| Registries | 1 | 2007 | 8090 | 0.010 |
Why?
|
| Time Factors | 1 | 2013 | 40038 | 0.010 |
Why?
|
| Young Adult | 1 | 2016 | 56392 | 0.010 |
Why?
|
| Adolescent | 1 | 2016 | 85729 | 0.000 |
Why?
|
| Follow-Up Studies | 1 | 2007 | 39001 | 0.000 |
Why?
|
| Retrospective Studies | 1 | 2013 | 77410 | 0.000 |
Why?
|
| Prospective Studies | 1 | 2007 | 53250 | 0.000 |
Why?
|
| Animals | 1 | 2013 | 168660 | 0.000 |
Why?
|